glp 1 kidney protection Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic disease: an approach for the nephrologist GLP-1 mediated diuresis and natriuresis
Description
Plainsboro, NJ: Novo Nordisk
Compounded oral tablets from MEDVi or Willow are not FDA-approved and have no reviewed equivalence
This points to the hypothesis that chronic hyperglycemia in diabetes, along with dysregulated central sensing of glucose concentrations in diabetics, may impair central transport of GLP-1 receptor agonist and explain the reduced efficacy for weight loss in type two diabetic patients. Geisler also discussed astrocytes
Why GLP-1 Agonists May Increase Kidney Stone Risk The primary mechanism linking GLP-1 agonists to kidney stones is dehydration
